142 related articles for article (PubMed ID: 35430345)
21. Weighted gene co-expression network reveals driver genes contributing to phenotypes of anaplastic thyroid carcinoma and immune checkpoint identification for therapeutic targets.
Dong X; Yang Y; Hou J; Chen W; Yuan Q; Xu G; Liu J; Li C; Wu G
Front Oncol; 2022; 12():1018479. PubMed ID: 36530988
[TBL] [Abstract][Full Text] [Related]
22. CSPG4 Is a Potential Therapeutic Target in Anaplastic Thyroid Cancer.
Egan CE; Stefanova D; Ahmed A; Raja VJ; Thiesmeyer JW; Chen KJ; Greenberg JA; Zhang T; He B; Finnerty BM; Zarnegar R; Jin MM; Scognamiglio T; Dephoure N; Fahey T; Min IM
Thyroid; 2021 Oct; 31(10):1481-1493. PubMed ID: 34078123
[No Abstract] [Full Text] [Related]
23. Transcript-level regulation of MALAT1-mediated cell cycle and apoptosis genes using dual MEK/Aurora kinase inhibitor "BI-847325" on anaplastic thyroid carcinoma.
Samimi H; Haghpanah V; Irani S; Arefian E; Sohi AN; Fallah P; Soleimani M
Daru; 2019 Jun; 27(1):1-7. PubMed ID: 31077090
[TBL] [Abstract][Full Text] [Related]
24. miR-148a inhibits self-renewal of thyroid cancer stem cells via repressing INO80 expression.
Sheng W; Chen Y; Gong Y; Dong T; Zhang B; Gao W
Oncol Rep; 2016 Dec; 36(6):3387-3396. PubMed ID: 27779717
[TBL] [Abstract][Full Text] [Related]
25. Identification of an immune-related key gene, PPARGC1A, in the development of anaplastic thyroid carcinoma: in-silico study and in-vitro evaluation.
Huang Y; Ling J; Chang A; Ye H; Zhao H; Zhuo X
Minerva Endocrinol (Torino); 2022 Jun; 47(2):150-159. PubMed ID: 32720497
[TBL] [Abstract][Full Text] [Related]
26. Identification of key pathways and biomarkers in anaplastic thyroid cancer using an integrated analysis.
Zhou J; Dong S; Shi C
J BUON; 2020; 25(6):2690-2699. PubMed ID: 33455115
[TBL] [Abstract][Full Text] [Related]
27. Targeted inhibition of long non-coding RNA H19 blocks anaplastic thyroid carcinoma growth and metastasis.
Zhang H; Yu Y; Zhang K; Liu X; Dai Y; Jiao X
Bioengineered; 2019 Dec; 10(1):306-315. PubMed ID: 31299871
[TBL] [Abstract][Full Text] [Related]
28. Novel role of ASH1L histone methyltransferase in anaplastic thyroid carcinoma.
Xu B; Qin T; Yu J; Giordano TJ; Sartor MA; Koenig RJ
J Biol Chem; 2020 Jun; 295(26):8834-8845. PubMed ID: 32398261
[TBL] [Abstract][Full Text] [Related]
29. OVOL2 impairs RHO GTPase signaling to restrain mitosis and aggressiveness of Anaplastic Thyroid Cancer.
Gugnoni M; Manzotti G; Vitale E; Sauta E; Torricelli F; Reggiani F; Pistoni M; Piana S; Ciarrocchi A
J Exp Clin Cancer Res; 2022 Mar; 41(1):108. PubMed ID: 35337349
[TBL] [Abstract][Full Text] [Related]
30. Knockdown of HCP5 exerts tumor-suppressive functions by up-regulating tumor suppressor miR-128-3p in anaplastic thyroid cancer.
Chen J; Zhao D; Meng Q
Biomed Pharmacother; 2019 Aug; 116():108966. PubMed ID: 31102936
[TBL] [Abstract][Full Text] [Related]
31. Thyroid Follicular Cell Loss of Differentiation Induced by MicroRNA miR-17-92 Cluster Is Attenuated by CRISPR/Cas9n Gene Silencing in Anaplastic Thyroid Cancer.
Fuziwara CS; Saito KC; Kimura ET
Thyroid; 2020 Jan; 30(1):81-94. PubMed ID: 31578932
[No Abstract] [Full Text] [Related]
32. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
[TBL] [Abstract][Full Text] [Related]
33. LncRNA AFAP-AS1 promotes anaplastic thyroid cancer progression by sponging miR-155-5p through ETS1/ERK pathway.
Ning M; Qin S; Tian J; Wang Y; Liu Q
Bioengineered; 2021 Dec; 12(1):1543-1554. PubMed ID: 33999777
[TBL] [Abstract][Full Text] [Related]
34. EIF5A2 Is Highly Expressed in Anaplastic Thyroid Carcinoma and Is Associated With Tumor Growth by Modulating TGF- Signals.
Hao F; Zhu Q; Lu L; Sun S; Huang Y; Zhang J; Liu Z; Miao Y; Jiao X; Chen D
Oncol Res; 2020 Sep; 28(4):345-355. PubMed ID: 32138807
[TBL] [Abstract][Full Text] [Related]
35. BRAFV600E restructures cellular lactylation to promote anaplastic thyroid cancer proliferation.
Wang X; Ying T; Yuan J; Wang Y; Su X; Chen S; Zhao Y; Zhao Y; Sheng J; Teng L; Luo C; Wang W
Endocr Relat Cancer; 2023 Aug; 30(8):. PubMed ID: 37184950
[TBL] [Abstract][Full Text] [Related]
36. Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target.
von Roemeling CA; Marlow LA; Pinkerton AB; Crist A; Miller J; Tun HW; Smallridge RC; Copland JA
J Clin Endocrinol Metab; 2015 May; 100(5):E697-709. PubMed ID: 25675381
[TBL] [Abstract][Full Text] [Related]
37. Integrated analysis of novel macrophage related signature in anaplastic thyroid cancer.
Luo Y; Yang YC; Ma B; Xu WB; Liao T; Wang Y
Endocrine; 2022 Dec; 78(3):517-530. PubMed ID: 36070052
[TBL] [Abstract][Full Text] [Related]
38. IL2RA
Pan Z; Bao L; Lu X; Hu X; Li L; Chen J; Jin T; Zhang Y; Tan Z; Huang P; Ge M
Biochim Biophys Acta Mol Basis Dis; 2023 Jan; 1869(1):166591. PubMed ID: 36328145
[TBL] [Abstract][Full Text] [Related]
39. Changes in the expression pattern of apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during progression of thyroid malignancy and their clinical significance.
Selemetjev SA; Savin SB; Paunovic IR; Tatic SB; Cvejic D
Wien Klin Wochenschr; 2015 May; 127(9-10):337-44. PubMed ID: 25471003
[TBL] [Abstract][Full Text] [Related]
40. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing.
Duan H; Li Y; Hu P; Gao J; Ying J; Xu W; Zhao D; Wang Z; Ye J; Lizaso A; He Y; Wu H; Liang Z
Histopathology; 2019 Dec; 75(6):890-899. PubMed ID: 31230400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
